Since one of our overall goals is the application of the PDE system for evaluating responses to immune checkpoint inhibitors, we further examined the complexity of the BC-PDE immune microenvironment by staining for CD4, CD8, FOXP3 and cytokeratin (Fig. 7A). The gene discussed is CD8A; the disease is breast cancer.